Company · founded 1998

Microbiotix (United States)

Worcester, United States · microbiotix.com

Manage this page

Citations, last 5 years: 65
Works, last 5 years: 16
h-index: 80
Scientists listed: 5
Grants since 2016: 69

Grants received

2017–2022 · research · R01

Oxadiazole Inhibitors of Non-Stop Ribosome Rescue to treat MDR Neisseria gonorrhoeae

Zachary David Aron · Microbiotix (United States) · funded by National Institutes of Health

$1.1MReproductive tract infections research

2017–2018 · research · R43

Screening for rAAV transduction enhancers

Terry L. Bowlin · Microbiotix (United States) · funded by National Institutes of Health

$300kVirus-based gene therapy research

2017–2019 · research · R43

Aminospectinomycin antibacterials for the treatment of antibiotic-resistant gonorrhea and other bacterial STDs

Michelle M. Butler · Microbiotix (United States) · funded by National Institutes of Health

$296.8kReproductive tract infections research

2017–2022 · research · R01

Oxadiazole Inhibitors of Non-Stop Ribosome Rescue to treat MDR Neisseria gonorrhoeae

Zachary David Aron · Microbiotix (United States) · funded by National Institutes of Health

$1.1MReproductive tract infections research

2017–2019 · research · R43

Screening for rAAV transduction enhancers

Terry L. Bowlin · Microbiotix (United States) · funded by National Institutes of Health

$290.6kVirus-based gene therapy research

2017–2020 · research · R43

Development of small molecule TLR5 inhibitors for rheumatoid arthritis therapy

Zachary David Aron · Microbiotix (United States) · funded by National Institutes of Health

$208.1kImmune Response and Inflammation

2017–2024 · research · R44

Screening for rAAV transduction enhancers

Terry L. Bowlin · Microbiotix (United States) · funded by National Institutes of Health

$986.7kVirus-based gene therapy research

2017–2024 · research · R01

Oxadiazole Inhibitors of Non-Stop Ribosome Rescue to treat MDR Neisseria gonorrhoeae

Michelle M. Butler · Microbiotix (United States) · funded by National Institutes of Health

$1.1MReproductive tract infections research

2017–2024 · research · R44

Screening for rAAV transduction enhancers

Terry L. Bowlin · Microbiotix (United States) · funded by National Institutes of Health

$1,000kVirus-based gene therapy research

2017–2021 · research · R43

Aminospectinomycin antibacterials for the treatment of antibiotic-resistant gonorrhea and other bacterial STDs

Michelle M. Butler · Microbiotix (United States) · funded by National Institutes of Health

$289kReproductive tract infections research

2017–2025 · research · R44

Screening for rAAV transduction enhancers

Terry L. Bowlin · Microbiotix (United States) · funded by National Institutes of Health

$987.8kVirus-based gene therapy research

2017–2020 · research · R43

Inhibitors of Pseudomonas aeruginosa efflux pumps to combat multi-drug resistance

Timothy J. Opperman · Microbiotix (United States) · funded by National Institutes of Health

$294.8kAntibiotic Resistance in Bacteria

2017–2019 · research · R43

Development of small molecule TLR5 inhibitors for rheumatoid arthritis therapy

Zachary David Aron · Microbiotix (United States) · funded by National Institutes of Health

$224.6kImmune Response and Inflammation

2017–2022 · research · R01

Oxadiazole Inhibitors of Non-Stop Ribosome Rescue to treat MDR Neisseria gonorrhoeae

Zachary David Aron · Microbiotix (United States) · funded by National Institutes of Health

$1.4MReproductive tract infections research

2016–2019 · research · R41

Inhibitors of the viral nucleoprotein-polymerase co-factor interaction for human RSV and MPV therapy

Donald T Moir · Microbiotix (United States) · funded by National Institutes of Health

$284.8kRespiratory viral infections research

2016–2018 · research · R41

T3SS needle protein inhibitors for the treatment of P. aeruginosa infection

Joan C Mecsas · Microbiotix (United States) · funded by National Institutes of Health

$303k

2016–2019 · research · R43

Novel beta-lactams as inhibitors of ebola virus infections

Zachary David Aron · Microbiotix (United States) · funded by National Institutes of Health

$297.4kViral Infections and Outbreaks Research

2016–2018 · research · R43

Novel beta-lactams as inhibitors of ebola virus infections

Zachary David Aron · Microbiotix (United States) · funded by National Institutes of Health

$304.4kViral Infections and Outbreaks Research

2016–2018 · research · R41

Inhibitors of the viral nucleoprotein-polymerase co-factor interaction for human RSV and MPV therapy

Donald T Moir · Microbiotix (United States) · funded by National Institutes of Health

$300kRespiratory viral infections research

2016–2019 · research · R41

T3SS needle protein inhibitors for the treatment of P. aeruginosa infection

Joan C Mecsas · Microbiotix (United States) · funded by National Institutes of Health

$297.8k

2012–2022 · research · R44

Optimization of novel pyranopyridine efflux pump inhibitors

Timothy J. Opperman · Microbiotix (United States) · funded by National Institutes of Health

$981.1kAntibiotic Resistance in Bacteria

2012–2024 · research · R44

Novel Spectinamide Antibiotics for the Treatment of MDR/XDR Tuberculosis

Michelle M. Butler · Microbiotix (United States) · funded by National Institutes of Health

$996.8kTuberculosis Research and Epidemiology

2012–2021 · research · R44

Novel Plasmodial Surface Anion Channel Inhibitors as Antimalarial Drugs

Michelle M. Butler · Microbiotix (United States) · funded by National Institutes of Health

$991.9k

2012–2022 · research · R44

Novel Spectinamide Antibiotics for the Treatment of MDR/XDR Tuberculosis

Michelle M. Butler · Microbiotix (United States) · funded by National Institutes of Health

$1MTuberculosis Research and Epidemiology

2012–2024 · research · R44

Optimization of novel pyranopyridine efflux pump inhibitors

Timothy J. Opperman · Microbiotix (United States) · funded by National Institutes of Health

$1MAntibiotic Resistance in Bacteria

2012–2021 · research · R44

Novel Plasmodial Surface Anion Channel Inhibitors as Antimalarial Drugs

Michelle M. Butler · Microbiotix (United States) · funded by National Institutes of Health

$1,000k

2012–2022 · research · R44

Novel Spectinamide Antibiotics for the Treatment of MDR/XDR Tuberculosis

Michelle M. Butler · Microbiotix (United States) · funded by National Institutes of Health

$999.6kTuberculosis Research and Epidemiology

2012–2023 · research · R44

Novel Plasmodial Surface Anion Channel Inhibitors as Antimalarial Drugs

Michelle M. Butler · Microbiotix (United States) · funded by National Institutes of Health

$982.5k

2012–2022 · research · R44

Optimization of novel pyranopyridine efflux pump inhibitors

Timothy J. Opperman · Microbiotix (United States) · funded by National Institutes of Health

$987.7kAntibiotic Resistance in Bacteria